Victoza will 'not be overnight success' in China
This article was originally published in Scrip
Executive Summary
Novo Nordisk does not expect its type 2 diabetes treatment Victoza (liraglutide) to become "a huge product overnight" in China, following approval of the drug by the State Food and Drug Administration (SFDA). However, it intends to use its "extensive experience and leadership market position" in China, where it has "70% of the insulin market", to boost uptake of the once-daily human glucagon-like peptide-1 (GLP-1) analogue, which is approved as an add-on to metformin or sulfonylurea, chief science officer Mads Krogsgaard Thomsen told Scrip.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.